Core Insights - Boehringer Ingelheim has licensed a pre-clinical program from Kyowa Kirin to develop a potential first-in-class small molecule for autoimmune diseases [1][3] - Autoimmune diseases affect approximately one in ten people globally, highlighting a significant unmet medical need for effective treatments [2][6] - The agreement allows Boehringer Ingelheim exclusive worldwide rights to develop the small molecule, with Kyowa Kirin eligible to receive up to €640 million in various payments and royalties [3] Company Overview - Boehringer Ingelheim is a biopharmaceutical company focused on human and animal health, emphasizing innovative therapies for high unmet medical needs [4] - Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company with over 70 years of experience in drug discovery and biotechnology innovation [5]